Prescribing patterns and healthcare costs of gout

References

• Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67:2557–2568.
   Google Scholar
• Maiuolo J, Oppedisano F, Gratteri S, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016;213:8–14.
   PubMed Web of Science ®Google Scholar
• Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Curr Rheumatol Rep. 2014;16(2):400.
   PubMed Web of Science ®Google Scholar
• Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26:186–191.
   PubMed Web of Science ®Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64:1431–1446.
   PubMed Web of Science ®Google Scholar
• Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64:1447–1461.
   PubMed Web of Science ®Google Scholar
• Taiwan Rheumatology Association. Taiwan guideline for management of gout and hyperuricemia updated 2016 [Internet] [cited 2017 Jun 9]. Available from: http://www.rheumatology.org.tw/news/News_Info.asp?/341.html
   Google Scholar
• Becker MA, MacDonald PA, Hunt BJ, et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27:585–591.
   PubMed Web of Science ®Google Scholar
• Doghramji PP, Wortmann RL. Hyperuricemia and gout: new concepts in diagnosis and management. Postgrad Med. 2012;124:98–109.
   PubMed Web of Science ®Google Scholar
• Rothenbacher D, Primatesta P, Ferreira A, et al. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011;50:973–981.
   PubMed Web of Science ®Google Scholar
• Wood R, Fermer S, Ramachandran S, et al. Patients with gout treated with conventional urate-lowering therapy: association with disease control, health-related quality of life, and work productivity. J Rheumatol. 2016;43:1897–1903.
   PubMed Web of Science ®Google Scholar
• Keenan RT. Limitations of the current standards of care for treating gout and crystal deposition in the primary care setting: a review. Clin Ther. 2017;39:430–441.
   PubMed Web of Science ®Google Scholar
• Rashid N, Levy GD, Wu YL, et al. Patient and clinical characteristics associated with gout flares in an integrated healthcare system. Rheumatol Int. 2015;35:1799–1807.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009;48:582–586.
   PubMed Web of Science ®Google Scholar
• Majdan M, Borys O. Gout and comorbidities associated with hyperuricemia. Ann Acad Med Stetin. 2010;56(Suppl 1):34–39.
   PubMedGoogle Scholar
• Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125:679–687.e1.
   PubMed Web of Science ®Google Scholar
• Karis E, Crittenden DB, Pillinger MH. Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street. South Med J. 2014;107:235–241.
   PubMed Web of Science ®Google Scholar
• Jackson R, Shiozawa A, Buysman EK, et al. Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis. BMJ Open. 2015;5:e007214.
   PubMed Web of Science ®Google Scholar
• Saseen JJ, Agashivala N, Allen RR, et al. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford). 2012;51:2004–2012.
   PubMed Web of Science ®Google Scholar
• Lynch W, Chan W, Kleinman N, et al. Economic burden of gouty arthritis attacks for employees with frequent and infrequent attacks. Popul Health Manag. 2013;16:138–145.
   PubMed Web of Science ®Google Scholar
• Kuo CF, Grainge MJ, See LC, et al. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther. 2015;17:13.
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Forsythe A, Guérin A, et al. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther. 2012;19(6):e157–166.
   PubMedGoogle Scholar
• Xu FJ. Analysis of gout patients’ health services utilization [master’s thesis]. China Medical University; 2003.
   Google Scholar
• Pujalte GG, Albano-Aluquin SA. Differential diagnosis of polyarticular arthritis. Am Fam Physician. 2015;92:35–41.
   PubMed Web of Science ®Google Scholar
• Burns CM, Wortmann RL. Latest evidence on gout management: what the clinician needs to know. Ther Adv Chronic Dis. 2012;3:271–286.
   PubMedGoogle Scholar
• Sicras-Mainar A, Navarro-Artieda R, Ibanez-Nolla J. Resource use and economic impact of patients with gout: a multicenter, population-wide study. Reumatol Clin. 2013;9:94–100.
   PubMedGoogle Scholar
• Morlock R, Chevalier P, Horne L, et al. Disease control, health resource use, healthcare costs, and predictors in gout patients in the United States, the United Kingdom, Germany, and France: a retrospective analysis. Rheumatol Ther. 2016;3(1):53–75.
   PubMed Web of Science ®Google Scholar
• Park H, Rascati KL, Prasla K, et al. Evaluation of health care costs and utilization patterns for patients with gout. Clin Ther. 2012;34:640–652.
   PubMed Web of Science ®Google Scholar
• Halpern R, Mody RR, Fuldeore MJ, et al. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25:1711–1719.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Patel PA, Yu AP, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 2008;14:164–175.
   PubMed Web of Science ®Google Scholar